UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 676

Sortiert nach

Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score

European journal of cancer (1990), 2017-11, Vol.86, p.135-142

2017

Volltextzugriff (PDF)

FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort

Annals of surgical oncology, 2015-01, Vol.22 (1), p.295-301

2015

Volltextzugriff (PDF)

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

The New England journal of medicine, 2018-07, Vol.379 (1), p.54-63

2018

Volltextzugriff (PDF)

Efficacy and safety of the Met inhibitor tepotinib in patients (pts) with advanced Met+ hepatocellular carcinoma (HCC) previously treated with sorafenib

Annals of oncology, 2018-11, Vol.29, p.ix48-ix48

2018

Volltextzugriff (PDF)

Carcinome hépatocellulaire : nouveautés épidémiologiques et démarche diagnostique

Oncologie (Paris, France), 2017-06, Vol.19 (5-6), p.135-143

Blanc, J. -F.

2017

Volltextzugriff (PDF)

Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial

British journal of cancer, 2007-10, Vol.97 (7), p.862-867

2007

Volltextzugriff (PDF)

Hepatic angiosarcoma: A suggestive pattern of enhancement on dynamic MR imaging

Diagnostic and interventional imaging, 2015-03, Vol.96 (3), p.293-295

2015

Volltextzugriff (PDF)

Predictive factors of depressive symptoms of elderly patients with cancer receiving first‐line chemotherapy

Psycho-oncology (Chichester, England), 2017-01, Vol.26 (1), p.15-21

2017

Volltextzugriff (PDF)

Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Prognosis, efficacy, and safety by liver disease etiology

Annals of oncology, 2016-10, Vol.27, p.vi209-vi209

2016

Volltextzugriff (PDF)

Phase II efficacy and safety data for the MET inhibitor tepotinib in patients (pts) with sorafenib-treated advanced hepatocellular carcinoma (HCC)

Annals of oncology, 2018-10, Vol.29, p.viii235-viii235

2018

Volltextzugriff (PDF)

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH)

Annals of oncology, 2018-10, Vol.29, p.viii208-viii208

2018

Volltextzugriff (PDF)

Assessment of disease burden in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)

Annals of oncology, 2018-10, Vol.29, p.viii237-viii237

2018

Volltextzugriff (PDF)

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH)

Annals of oncology, 2018-06, Vol.29, p.v122-v122

2018

Volltextzugriff (PDF)

Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma

The Journal of pathology, 1999-09, Vol.189 (1), p.46-52

1999

Volltextzugriff (PDF)

Comparison of perfused volume segmentation between cone-beam CT and 99mTc-MAA SPECT/CT for treatment dosimetry before selective internal radiation therapy using 90Y-glass microspheres

Diagnostic and interventional imaging, 2021-01, Vol.102 (1), p.45-52

2021

Volltextzugriff (PDF)

Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumor classification

Journal of hepatology, 2017, Vol.66 (1), p.S462-S462

2017

Volltextzugriff (PDF)

Proteomic analysis identifies argininosuccinate synthase 1 as a useful biomarker for hepatocellular adenoma classification and patient management

Journal of hepatology, 2017, Vol.66 (1), p.S228-S229

2017

Volltextzugriff (PDF)

Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy

Annals of oncology, 2016-10, Vol.27, p.vi211-vi211

2016

Volltextzugriff (PDF)

Bi-allelic inactivation of TCF1 in hepatic adenomas

Nature genetics, 2002-10, Vol.32 (2), p.312-315

2002

Volltextzugriff (PDF)

Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC)

Annals of oncology, 2017-09, Vol.28, p.v617-v617

2017

Volltextzugriff (PDF)

PD-020Tolerability and activity of second-line tepotinib, a potent and highly selective c-MET inhibitor, in patients with advanced hepatocellular carcinoma previously treated with sorafenib

Annals of oncology, 2016-06, Vol.27 (suppl_2), p.ii109-ii109

2016

Volltextzugriff (PDF)

Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy

Annals of oncology, 2016-10, Vol.27, p.vi234-vi234

2016

Volltextzugriff (PDF)

Multidisciplinary meetings specific to hepatocellular carcinoma: How to proceed?

Journal of visceral surgery, 2019-06, Vol.156 (3), p.217-227

2019

Volltextzugriff (PDF)

Recurrent INHBE-GLI1 fusions in hepatocellular adenomas with sonic hedgehog pathway activation

Journal of hepatology, 2017, Vol.66 (1), p.S14-S14

2017

Volltextzugriff (PDF)

1 – 25 von 676

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(515)
Mit Volltextzugriff
(469)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Hepatology
(36)
Annals Of Oncology
(31)
La Presse Médicale
(25)
Astronomy And Astrophysics
(16)
Gastroentérologie Clinique Et Biologique
(13)
Médecine Tropicale
(12)
La Revue De Medecine Interne
(11)
Pédiatrie
(10)
Astronomy & Astrophysics
(9)
Physical Review. C
(9)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score

FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

Efficacy and safety of the Met inhibitor tepotinib in patients (pts) with advanced Met+ hepatocellular carcinoma (HCC) previously treated with sorafenib

Carcinome hépatocellulaire : nouveautés épidémiologiques et démarche diagnostique

Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial

Hepatic angiosarcoma: A suggestive pattern of enhancement on dynamic MR imaging

Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)

Predictive factors of depressive symptoms of elderly patients with cancer receiving first‐line chemotherapy

Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Prognosis, efficacy, and safety by liver disease etiology

Phase II efficacy and safety data for the MET inhibitor tepotinib in patients (pts) with sorafenib-treated advanced hepatocellular carcinoma (HCC)

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Patient reported outcome results across two phase III studies (REACH-2 and REACH)

Assessment of disease burden in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)

Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH)

Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma

Comparison of perfused volume segmentation between cone-beam CT and 99mTc-MAA SPECT/CT for treatment dosimetry before selective internal radiation therapy using 90Y-glass microspheres

Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumor classification

Proteomic analysis identifies argininosuccinate synthase 1 as a useful biomarker for hepatocellular adenoma classification and patient management

Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy

Bi-allelic inactivation of TCF1 in hepatic adenomas

Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC)

PD-020Tolerability and activity of second-line tepotinib, a potent and highly selective c-MET inhibitor, in patients with advanced hepatocellular carcinoma previously treated with sorafenib

Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy

Multidisciplinary meetings specific to hepatocellular carcinoma: How to proceed?

Recurrent INHBE-GLI1 fusions in hepatocellular adenomas with sonic hedgehog pathway activation

Suchergebnisse filtern